Alchem Synthon: Pioneer In Specialty & Fine Chemicals Segment

D. S. Rane

Managing Director

D. S. Rane

Managing Director

The growth of specialty chemicals is attributed to the growing demand from pharmaceuticals, food and feed additives, flavours and fragrances among others. As per a report, the global specialty and fine chemicals market size was valued at USD 616.2 billion in 2022 and is anticipated to witness a compound annual growth rate (CAGR) of 5.1 percent from 2023 to 2030. The rising popula¬tion and rapidly growing industrialization within the country have been accounting for the growth of specialty chemicals market. Additionally, market forecast states that the people with purchasing power have also increased within this geo¬graphic spread. Mainly, customers are looking for good quali¬ty products at affordable rates.

Established in the year 2007, Alchem Synthon has de¬veloped innovative technology based products and created its footprints in the pharmaceutical, specialty, performance and fine chemical industry as a trusted partner. The com¬pany is mainly focusing on manufacturing anti-HIV and an¬ti-cancer drugs as well as drugs for central nervous system where doses are very small but efficacy is very high. Alchem Synthon was initially started as a technology development driven organization and is currently manufacturing more than 30 products. All these products are developed in its well-equipped research center.

“We believe that innovation should not be limited to new technologies or products but it should provide value to its customers as well as the employees”, says D. S. Rane, Managing Director.

Focused on Innovation & Continuous R&D
Alchem Synthon is an ISO 9001:2015 & GMP certified compa¬ny. Alchem Synthon has proficiency in manufacturing phar¬maceutical intermediates that form the building blocks of the active pharmaceutical ingredient (API). The core strength of Alchem Synthon lies in synthetic organic chemistry. The firm also derives its strength from its highly dedicated team of professionals that are specialized and possess rich industry experience in synthetic chemistry. The company has always believed in creating organizational culture which supports innovation and hence it consistently follows innovative ap¬proaches to become more productive.

Alchem Synthon strikes to attract and retain the best tal¬ent in the industry and back them up with proper infrastruc-ture and systems. It has a wide infrastructure that consists of 6000 square feet of working space. Alchem Synthon has DSIR approved research and development lab. Its laboratories are well equipped with instruments and equipment to support the various research and development analysis and manufac¬turing activities. Alchem Synthon has a comprehensive busi¬ness continuity and disaster recovery plan. The company also has well established systems to maintain data confidentiality while working with multiple clients and has an impeccable track record over the last 10 plus years.

We Believe That Innovation Should Not Be Limited To New Technologies Or Products But It Should Provide Value To Its Customers As Well As The Employees
D. S. Rane //Managing Director

The firm is developing & manufacturing performance and fine chemicals mainly for polymer industry apart from the high volume pharmaceutical intermediates. The company has a broad clientele that consists of Cipla, Dr. Reddy’s, Sun Pharmaceutical Industries, Aurobindo and many more. The company has tie-up with Mitsubishi which is a Japan based company and moving forward it is focusing to manufacture some performance based as well as space related chemicals with them. Also with Neuron of USA, the firm is developing metal treatment chemicals that will be used for purification in the coming future.